Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI - Trial NCT06009874
Access comprehensive clinical trial information for NCT06009874 through Pure Global AI's free database. This phase not specified trial is sponsored by Mohammad Hussien Tantawy Soliman and is currently Recruiting. The study focuses on Myocardial Infarction. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mohammad Hussien Tantawy Soliman
Tanta University
Timeline & Enrollment
N/A
Oct 01, 2023
Aug 01, 2026
Primary Outcome
difference in infarct size,difference in NT-proBNP level
Summary
This study aims to investigate the effect of early administration of DAPA during ischemia and
 before pPCI on infarct size, reperfusion injury-related myocardial damage, cardioprotection
 from HF, and renoprotection from AKI in patients with AMI.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06009874
Non-Device Trial